🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

92+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 92 recruiting trials for “Cystic fibrosis

NARecruitingNCT06273566

French Validation of the AdT-Physio Scale

🏥 Pole Sante Grace de Dieu📍 1 site📅 Started Apr 2024View details ↗
RecruitingNCT06327802

Improving the Well-being of Caregivers of Cystic Fibrosis Patients During Physiotherapy Treatment

🏥 Pole Sante Grace de Dieu📍 1 site📅 Started Apr 2024View details ↗
Phase 1, PHASE2RecruitingNCT06016088

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

🏥 Respirion Pharmaceuticals Pty Ltd📍 22 sites📅 Started Apr 2024View details ↗
NARecruitingNCT06350149

A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis

👨‍⚕️ Tanicia Daley, MD, MPH, Emory University📍 1 site📅 Started Mar 2024View details ↗
RecruitingNCT06302270

CFTR Modulators in Pregnancy and Postpartum

🏥 Region Stockholm📍 1 site📅 Started Mar 2024View details ↗
NARecruitingNCT07192679

MAGNIFY - Pulmonary Magnetic Resonance Imaging for Cystic Fibrosis

👨‍⚕️ Jim Wild, Professor📍 1 site📅 Started Feb 2024View details ↗
RecruitingNCT06251622

Muscle Function and Physical Activity in the Modern Era of Cystic Fibrosis

🏥 Hospices Civils de Lyon📍 1 site📅 Started Feb 2024View details ↗
Enrolling by InvitationNCT06262282

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

👨‍⚕️ Jerry Nick, MD, National Jewish Health📍 18 sites📅 Started Feb 2024View details ↗
Phase 2RecruitingNCT06237335

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

👨‍⚕️ John Matthews, MBBS, MCRP, PhD, ReCode Therapeutics, Inc.📍 20 sites📅 Started Feb 2024View details ↗
EARLY_Phase 1RecruitingNCT06339593

Regional Monitoring of CF Lung Disease

👨‍⚕️ Jason C Woods, PhD, Cincinnati Children's Hospital Medica Center📍 1 site📅 Started Jan 2024View details ↗
NARecruitingNCT06284577

Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis

🏥 Oslo University Hospital📍 1 site📅 Started Jan 2024View details ↗
RecruitingNCT05982795

Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome

👨‍⚕️ Ryan E Little, MD, Dartmouth-Hitchcock Medical Center📍 1 site📅 Started Nov 2023View details ↗
RecruitingNCT06599892

CF Organization of Care in the Era of Highly Effective Modulator.

👨‍⚕️ Philippe REIX, Professor, Hospices Civils de Lyon📍 1 site📅 Started Sep 2023View details ↗
NARecruitingNCT05723445

The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes

👨‍⚕️ Kevin J Scully, MB BCh BAO, Rhode Island Hospital📍 2 sites📅 Started Sep 2023View details ↗
Phase 3Enrolling by InvitationNCT05844449

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

🏥 Vertex Pharmaceuticals Incorporated📍 37 sites📅 Started Aug 2023View details ↗
NARecruitingNCT05766774

FEED-Cystic Fibrosis (FEED-CF)

👨‍⚕️ Jessica A Alvarez, PhD, RD, Emory University📍 1 site📅 Started Jun 2023View details ↗
RecruitingNCT05934656

Understanding Gut Symptoms in People With Cystic Fibrosis

👨‍⚕️ Alan Smyth, University of Nottingham📍 1 site📅 Started Jun 2023View details ↗
NARecruitingNCT05818319

Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/tezacaftor/ivacaftor in Urine After a Short Pause of Therapy

👨‍⚕️ Jens G. Leipziger, Department of Biomedicine, Aarhus University, Denmark📍 1 site📅 Started Jun 2023View details ↗
EARLY_Phase 1RecruitingNCT06163482

Hormonal Responses to a Mixed Meal in People With Cystic Fibrosis

👨‍⚕️ Jason Winnick, PhD, University of Cincinnati📍 1 site📅 Started Mar 2023View details ↗
Phase 1, PHASE2RecruitingNCT05668741

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

🏥 Vertex Pharmaceuticals Incorporated📍 43 sites📅 Started Feb 2023View details ↗
← PreviousPage 3 of 5Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →